abrdn Life Sciences Investors
HQL
83 hedge funds and large institutions have $157M invested in abrdn Life Sciences Investors in 2026 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 47 increasing their positions, 13 reducing their positions, and 11 closing their positions.
262% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 13
16% more capital invested
Capital invested by funds: $135M → $157M (+$21.5M)
2.85% less ownership
Funds ownership: 28.73% → 25.88% (-2.8%)
3% less funds holding
Funds holding: 86 → 83 (-3)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.55M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$1.64M |
| 3 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$1.14M |
| 4 |
Rockefeller Capital Management
New York
|
+$834K |
| 5 |
LPL Financial
San Diego,
California
|
+$625K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Saba Capital Management
New York
|
-$15.4M |
| 2 |
SFS
Shaker Financial Services
Arlington,
Virginia
|
-$1.12M |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$947K |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
-$861K |
| 5 |
AIA
Absolute Investment Advisers
Rosemary Beach,
Florida
|
-$582K |
HQL Hedge Fund Activity: Q2 2026 in Review
83 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q2 2026, worth a combined $157M — up 16% from $135M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of HQL and 9 opened new positions — a net loss of 2 holders — while 13 trimmed existing stakes and 47 added.
The largest buyer was Morgan Stanley, adding an estimated $3.55M. The largest seller was Saba Capital Management, cutting an estimated $15.4M.
- 83 institutional investors held abrdn Life Sciences Investors (HQL) as of Q2 2026, down from 86 in Q1 2026.
- Funds reported $157M of abrdn Life Sciences Investors stock for Q2 2026, up 16% quarter-over-quarter.
- 9 funds opened new abrdn Life Sciences Investors positions in Q2 2026 and 11 closed out, a net change of -2 holders.
- The largest abrdn Life Sciences Investors buyer in Q2 2026 was Morgan Stanley, an estimated $3.55M added.
- The largest abrdn Life Sciences Investors seller in Q2 2026 was Saba Capital Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q2 2026.